Gilead Sciences Inc.: Access Program

Posted: 3 Apr 2010

See all articles by V. Kasturi Rangan

V. Kasturi Rangan

Harvard Business School - Marketing Unit

Katharine L. Lee

Harvard Business School

Date Written: February 3, 2010

Abstract

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.

Suggested Citation

Rangan, V. Kasturi and Lee, Katharine L., Gilead Sciences Inc.: Access Program (February 3, 2010). HBS Case No. 510-029; Harvard Business School Marketing Unit. Available at SSRN: https://ssrn.com/abstract=1581428

V. Kasturi Rangan (Contact Author)

Harvard Business School - Marketing Unit ( email )

Soldiers Field
Boston, MA 02163
United States

Katharine L. Lee

Harvard Business School ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Register to save articles to
your library

Register

Paper statistics

Abstract Views
478
PlumX